Back to results
US 2016/0102089 A1Published application
Arylpyrrolopyridine derived compounds as LRRK2 inhibitors
AssigneesH. Lundbeck A/S, Vernalis (R&D) Ltd
InventorsSimon Timothy Bedford, I-Jen Chen, Yikang Wang, Douglas Stewart Williamson
Life of this patent
Estimating the term…
Abstract
The present invention is directed to arylpyrrolopyridine derivatives of formula (A) (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease cancer.
Claims11
1-16. (canceled)
A compound of formula A
- wherein
- R1 is an NHR2 group,
- R2 is H or a 5 or 6 membered heteroaromatic ring with 1 or 2N, which heteroaromatic ring is optionally substituted with 1 or 2 groups each independently selected from the group consisting of CF3, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylamine and C1-C3 alkoxy amine,
- R3 is a 5 or 6 membered aromatic ring or a 5 or 6 membered heteroaromatic ring with 1 or 2 heteroatoms(s) selected from S and N, which aromatic ring or heteroaromatic ring is optionally substituted with H, 1 or 2C1-C3 alkyl, or a trifluoromethyl,
- L is absent or represents (CH2)n, n=1 or 2,
- R4 is H, NH2 or a 5 or 6 membered heterocylic ring with 1 or 2 heteroatom(s) selected from N and O, which heterocyclic ring is optionally substituted with 1 or 2 C1-C3 alkyl, 1 or 2C2-C3 alkoxy, 1 or 2C1-C3 alkyl amine or 1 or 2C2-C3 alkoxy amine,
- or a pharmaceutically acceptable salt thereof.
4 more elements
A compound of formula A
- wherein
- R1 is an NHR2 group,
- R2 is a heteroaromatic ring selected from the group consisting of
- optionally substituted with 1 or 2 groups each independently selected from the group consisting of CF3, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylamine and C1-C3 alkoxy amine, and *denotes the attachment point;
- R3 is a 5 or 6 membered aromatic ring or a 5 or 6 membered heteroaromatic ring with 1 or 2 heteroatoms(s) selected from S and N, which aromatic ring or heteroaromatic ring is optionally substituted with H, OH, 1 or 2C1-C3 alkyl, 1 or 2C1-C3 alkoxy or a trifluoromethyl,
- L is absent or represents (CH2)n, n=1 or 2,
- R4 is H, NH2 or a 5 or 6 membered heterocylic ring with 1 or 2 heteroatom(s) selected from N and O, which heterocyclic ring is optionally substituted with 1 or 2C1-C3 alkyl, 1 or 2C2-C3 alkoxy, 1 or 2C1-C3 alkyl amine or 1 or 2C2-C3 alkoxy amine,
- or a pharmaceutically acceptable salt thereof.
5 more elements
A compound of formula A
- wherein
- R1 is an NHR2 group,
- R2 is H or a 5 or 6 membered heteroaromatic ring with 1 or 2N, which heteroaromatic ring is optionally substituted with 1 or 2 groups each independently selected from the group consisting of CF3, halogen, C1-C3 alkyl, C1-C3 alkoxy, C1-C3 alkylamine and C1-C3 alkoxy amine,
- R3 is a 5 or 6 membered aromatic ring or a 5 or 6 membered heteroaromatic ring with 1 or 2 heteroatoms(s) selected from S and N, which aromatic ring or heteroaromatic ring is optionally substituted with H, OH, 1 or 2C1-C3 alkyl, 1 or 2C1-C3 alkoxy or a trifluoromethyl,
- L is absent or represents (CH2)n, n=1 or 2,
- and R4 is
- and
- *denotes the attachment point,
- or a pharmaceutically acceptable salt thereof.
6 more elements
Dependencies are inferred from the claim text.